Open Label Pilot Trial in Adults With Recent-onset T1D to Evaluate the Safety, Diabetes Status and Immune Response of GAD-antigen (Diamyd) Therapy Administered Into Lymph Nodes in Combination With an Oral Vitamin D Regimen

Trial Profile

Open Label Pilot Trial in Adults With Recent-onset T1D to Evaluate the Safety, Diabetes Status and Immune Response of GAD-antigen (Diamyd) Therapy Administered Into Lymph Nodes in Combination With an Oral Vitamin D Regimen

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs GAD65 vaccine (Diamyd) (Primary) ; Ergocalciferol
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms DIAGNODE; DIAGNODE-1
  • Most Recent Events

    • 27 Jul 2017 According to a Diamyd Medical media release, additional preliminary interim results were published in the New England Journal of Medicine.
    • 06 Jul 2017 Interim results (n=6) published in a Diamyd Medical Media Release.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top